- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01442259
An Open-label, Parallel-group Study to Determine the Pharmacokinetics of a Single Dose of AFQ056 in Subjects With Renal Impairment Compared to Healthy Subjects
An Open-label, Parallel-group Study to Determine the Pharmacokinetics of a Single Dose of AFQ056 in Subjects With Mild, Moderate or Severe Renal Impairment Compared to Age, Sex, and Body Weight-matched Healthy Subjects
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
-
Kiel, Tyskland
- Novartis Investigative Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Written informed consent must be obtained before any assessment is performed.
- Female subjects must be of non-child bearing potential as defined as postmenopausal females with no regular menstrual bleeding for at least 1 year prior to inclusion
- Body weight: ≥50kg; BMI: 18-34 kg/m2
- Ability to communicate well with the investigator and comply with the requirements of the study.
For subjects with renal impairment only
- No current clinically significant disease (other than renal impairment), except for stable underlying disease that caused renal impairment, as determined by clinical history and physical examination.
- MDRD-calculated eGFR of <90 mL/min/1.73 m2 based on serum creatinine
- Vital signs (after 3 minutes resting measured in the supine position) should be within normal ranges as deemed by the Investigator.
For healthy subjects only
- No current clinically significant disease as determined by clinical history and physical examination.
- MDRD-calculated eGFR of ≥90 mL/min/1.73 m2 based on serum creatinine.
- Vital signs (after 3 minutes resting measured in the supine position) should be within normal ranges as deemed by the Investigator.
Exclusion Criteria:
- Pregnant or nursing (lactating) females
Use of any prescription or over-the-counter (OTC) drugs, herbal (e.g. St. John's wort) ordietary supplements (e.g. broccoli, vitamins) within three weeks or five half lives(whichever is longer) prior to dosing with AFQ056 until study completion. This does not include drugs that are used as (symptomatic) treatment of renal impairment (e.g. antihypertensive and antidiabetic drugs) provided such drugs are:
- used at the same dose within three weeks or five half lives (whichever is longer) prior to dosing with AFQ056 until study completion.
- not known as inhibitors or inducers of CYP1A1, 1A2, 2C8, 2C9, 2C19, 3A4, 3A5 gp).
- Participation in any clinical investigation or use of any investigational drug within 30 days or five (5) half-lives of a given investigational drug (whichever period is longer); or longer if required by local regulations prior to screening until study completion
- Donation or loss of 400 mL or more of blood within 8 weeks prior to first dosing, or longer if required by local regulation.
- History of renal transplantation
- History or presence of prolonged QTc interval (males: >450ms; females: > 470 ms), 2nd or 3rd degree AV-block or any other clinically significant ECG abnormalities as determined by medical history and 12-lead ECG recordings at screening and baseline 1.
- History or presence of any clinically significant disease of any major system organ class, within the past 2 years prior to screening, except for renal impairment and underlying diseases causing renal impairment for the subject belonging to the renal impairment groups.
- Subjects undergoing any method of dialysis (hemodialysis or peritoneal dialysis)
- History of or ongoing active substance abuse (including alcohol) within the past 2 years.
- Smokers (use of tobacco products in the previous 3 months). Urine cotinine levels will be measured during Screening and at Baseline for all subjects. Smokers will be defined as any subject who reports tobacco use and/or who has a urine cotinine ≥ 500 ng/mL at screening
Other protocol-defined inclusion/exclusion criteria may apply.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: N/A
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: All study subjects
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Measure: Area under the plasma concentration-time curve from time zero to infinity (AUCinf)
Tidsramme: 0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
|
0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
|
Measure: Area under the curve from time zero to the last measurable concentration sampling time (Tlast) [mass x time x volume-1] (AUClast)
Tidsramme: 0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
|
0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
|
Measure: Maximum observed plasma concentration (Cmax)
Tidsramme: 0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
|
0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
|
Measure: Time to Reach Maximum Observed Plasma Concentration (Tmax)
Tidsramme: 0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
|
0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
|
Measure: Terminal elimination half-life (T1/2)
Tidsramme: 0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
|
0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
|
Measure: The apparent systemic (or total body) clearance from plasma following extravascular administration [volume / time] (CL/F)
Tidsramme: 0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
|
0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
|
Measure: The apparent volume of distribution during the terminal elimination phase following oral administration [volume] (Vz/F)
Tidsramme: 0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
|
0, 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 48, 72 hours post dose
|
Measure: Amount of drug excreted into the urine from time zero to time't' where t is a defined time point after administration [mass units or % of dose] (Ae0-t)
Tidsramme: 4 days
|
4 days
|
Measure: The renal clearance from plasma [volume / time] (CLr)
Tidsramme: 4 days
|
4 days
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Physical examination
Tidsramme: Screening, Day -1, Day 8 +/- 2 days
|
Screening, Day -1, Day 8 +/- 2 days
|
Measure: Vital signs and body measurements
Tidsramme: Screening, Day -1, Day 1, Day 8 +/- 2 days
|
Screening, Day -1, Day 1, Day 8 +/- 2 days
|
Measure: ECG
Tidsramme: Screening, Day -1, Day 1, Day 8 +/- 2 days
|
Screening, Day -1, Day 1, Day 8 +/- 2 days
|
Measure: pulse oximetry
Tidsramme: Screening, Day -1, Day 1, Day 8 +/- 2 days
|
Screening, Day -1, Day 1, Day 8 +/- 2 days
|
Measure: hematology
Tidsramme: Screening, Day -1, Day 4, Day 8 +/- 2 days
|
Screening, Day -1, Day 4, Day 8 +/- 2 days
|
Measure: blood chemistry
Tidsramme: Screening, Day -1, Day 2, Day 4, Day 8 +/- 2 days
|
Screening, Day -1, Day 2, Day 4, Day 8 +/- 2 days
|
Measure: urinalysis
Tidsramme: Screening, Day -1, Day 4, Day 8 +/- 2 days
|
Screening, Day -1, Day 4, Day 8 +/- 2 days
|
Measure: AE (adverse events) monitoring
Tidsramme: During the study (up to 10 days)
|
During the study (up to 10 days)
|
SAE (serious adverse events) monitoring
Tidsramme: During the study (up to 10 days) and up to 30 days after study completion
|
During the study (up to 10 days) and up to 30 days after study completion
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CAFQ056A2124
- 2010-022738-94 (EudraCT-nummer)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Mild Moderate
-
Tishreen UniversityFullførtMild til moderat fremre underkjevesegment CrowdindDen syriske arabiske republikk
-
Solta MedicalFullført
-
PfizerFullførtSunn | Ellers friske frivillige med mild eller moderat leverdysfunksjonForente stater
-
Beer, Kenneth R., M.D., PAMedicis Pharmaceutical CorporationFullførtMild til moderat temporal atrofi | Moderat til alvorlig Glabellar Rhytider | Moderat til alvorlig periorbital rytmeForente stater
-
Norwegian Institute of Public HealthGöteborg University; University of Bergen; University of Tromso; Sussex Partnership... og andre samarbeidspartnereRekrutteringAngst | Mild til moderat depresjonNorge
-
Etwal Ltd.FullførtMild til moderat psoriasisIsrael
-
Lipidor ABRekrutteringMild til moderat psoriasisIndia
-
Norwegian Institute of Public HealthGöteborg University; University of Bergen; The Research Council of Norway; Sussex...Fullført
-
Betta Pharmaceuticals Co., Ltd.Tigermed Consulting Co., LtdAvsluttetMild til moderat psoriasisKina
-
BioMAS LtdTilbaketrukket
Kliniske studier på AFQ056
-
Novartis PharmaceuticalsAvsluttetFragilt X-syndromTyskland, Forente stater, Sveits, Australia, Canada, Danmark, Frankrike, Italia, Storbritannia, Spania
-
Novartis PharmaceuticalsFullførtFragilt X-syndromForente stater, Spania
-
Novartis PharmaceuticalsFullførtFragilt X-syndromForente stater, Sveits, Tyskland, Australia, Canada, Danmark, Frankrike, Italia, Spania, Storbritannia
-
Novartis PharmaceuticalsFullførtNedsatt leverfunksjonTyskland, Forente stater, Ungarn
-
Novartis PharmaceuticalsAvsluttetFragilt X-syndromForente stater, Belgia, Australia, Israel, Sveits, Tyskland, Danmark, Italia, Nederland, Spania, Sverige, Storbritannia, Frankrike
-
Novartis PharmaceuticalsAvsluttetChorea | Huntingtons sykdomTyskland, Storbritannia
-
Novartis PharmaceuticalsFullførtFragilt X-syndromForente stater, Belgia, Australia, Israel, Sveits, Tyskland, Frankrike, Canada, Danmark, Indonesia, Italia, Nederland, Spania, Sverige, Tyrkia, Storbritannia
-
Elizabeth Berry-KravisNational Institute of Neurological Disorders and Stroke (NINDS); Novartis...Fullført
-
Yale UniversityFullførtFamiliær alkoholisme sårbarhetForente stater
-
Novartis PharmaceuticalsNational Institute on Drug Abuse (NIDA)TilbaketrukketKokainbruksforstyrrelse